Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is expanding ...

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended ...

Vertex Pharmaceuticals Incorporated remains a leader in cystic fibrosis treatments, fueling robust cash flow and funding a promising pipeline expansion. VRTX is seeing early but accelerating revenue ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a bullish ...